Treatment Strategies for Deficiency of Adenosine Deaminase 2
Amanda K. Ombrello(National Human Genome Research Institute), Daniel L. Kastner(National Institutes of Health), Camilo Toro(National Human Genome Research Institute), Beverly Barham(National Human Genome Research Institute), Ivona Aksentijevich(National Institutes of Health), Deborah L. Stone(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Ariane Soldatos(National Institute of Neurological Disorders and Stroke), Karyl S. Barron(National Institute of Allergy and Infectious Diseases), Natalie Deuitch(National Human Genome Research Institute), Anne Jones(National Human Genome Research Institute), Gineth Paola Pinto-Patarroyo(National Human Genome Research Institute), Parag Kumar(National Institutes of Health Clinical Center), Tina Romeo(National Human Genome Research Institute), Jing Qin(Memorial Sloan Kettering Cancer Center), Sherry L. Sheldon(National Institutes of Health Clinical Center), Qing Zhou(National Human Genome Research Institute), Ada Man(University of Manitoba), Susan J. Kelly(Duke Medical Center), Willy A. Flegel(National Institutes of Health Clinical Center), Patrycja Hoffmann(National Human Genome Research Institute), Michael S. Hershfield(Duke University)
Cited by 195
Related Papers
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
<i>STAT4</i> and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus
|New England Journal of Medicine|2007|1.1k
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
|New England Journal of Medicine|2006|902
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889